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Abstract
Background: The novel breast cancer metastasis modulator gene signal-induced proliferation-
associated 1 (Sipa1) underlies the breast cancer metastasis efficiency modifier locus Mtes 1 and has
been shown to influence mammary tumour metastatic efficiency in the mouse, with an ectopically
expressing Sipa1 cell line developing 1.5 to 2 fold more surface pulmonary metastases. Sipa1
encodes a mitogen-inducible GTPase activating (GAP) protein for members of the Ras-related
proteins; participates in cell adhesion and modulates mitogen-induced cell cycle progression.
Germline SIPA1 SNPs showed association with positive lymph node metastasis and hormonal
receptor status in a Caucasian cohort. We hypothesized that SIPA1 may also be correlated to
breast carcinoma incidence as well as prognosis. Therefore, this study investigated the potential
relationship of SIPA1 and human breast cancer incidence by a germline SNP genotype frequency
association study in a case-control Caucasian cohort in Queensland, Australia.
Methods: The SNPs genotyped in this study were identified in a previous study and the genotyping
assays were carried out using TaqMan SNP Genotyping Assays. The data were analysed with chi-
square method and the Monte Carlo style CLUMP analysis program.
Results: Results indicated significance with SIPA1 SNP rs3741378; the CC genotype was more
frequently observed in the breast cancer group compared to the disease-free control group,
indicating the variant C allele was associated with increased breast cancer incidence.
Conclusion: This observation indicates SNP rs3741378 as a novel potential sporadic breast cancer
predisposition SNP. While it showed association with hormonal receptor status in breast cancer
group in a previous pilot study, this exonic missense SNP (Ser (S) to Phe (F)) changes a hydrophilic
residue (S) to a hydrophobic residue (F) and may significantly alter the protein functions of SIPA1
in breast tumourgenesis. SIPA1 SNPs rs931127 (5' near gene), and rs746429 (synonymous (Ala (A)
to Ala (A)), did not show significant associations with breast cancer incidence, yet were associated
with lymph node metastasis in the previous study. This suggests that SIPA1 may be involved in
different stages of breast carcinogenesis and since this study replicates a previous study of the
associated SNP, it implicates variants of the SIPA1 gene as playing a potential role in breast cancer.
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Background
The novel breast cancer gene SIPA1 was originally identi-
fied as a candidate gene for breast cancer metastasis from
mouse studies. Mouse Sipa1 was established as a candi-
date for underlying the breast cancer metastasis efficiency
modifier locus Mtes 1 by Park et al [1]. The Mtes 1 loci in
the mouse genome were recognized as a genetic region
that substantially influenced the metastatic efficiency of
mammary tumours in the mouse. The mouse Mtes 1 locus
is orthologous to human chromosome 11q12-11q13,
which is known to harbor the metastasis suppressor gene
BRMS1. Utilizing a Multiple Cross Mapping strategy,
mouse Sipa1 was identified as a potential candidate for
the Mtes 1 locus and molecular research into Sipa1
revealed that cellular Sipa1 levels were correlated with cel-
lular metastatic capacity. Signal-induced proliferation-
associated 1 is further recognized as a metastasis modula-
tor gene, since an ectopically expressing Sipa1 cell line
developed about two fold more surface pulmonary metas-
tases compared to the control cell line [1].
Signal-induced proliferation-associated 1 is a mitogen-
inducible GTPase activating (GAP) protein for members
of the Ras-related proteins; Rap1 and Rap2, but not for
Ras, Rho, Cdc42, Rac and Ran, with comparable specific
activity to the rap1GAP encoded protein [2]. It was found
that the SIPA1 protein severely impedes mitogen-induced
cell cycle progression when abnormally and/or prema-
turely expressed [3]. Signal-induced proliferation-associ-
ated 1 was also found to participate in cell adhesion via
interaction with Rap1GTP activities. Park et al., 2005
demonstrated that Sipa1 suppression (via RNAi) induces
increased cell adhesion [1]. This study reported that a sin-
gle nucleotide polymorphism (SNP) in the mouse Sipa1
gene affects the binding efficiency of the protein to its
partner protein. This polymorphism was identified in the
PDZ binding domain of the Sipa1 protein between the
mouse DBA strain and the mouse FVB strain, with the
binding efficiency of the Sipa1 protein is higher in the
mouse DBA strain allele compared to the mouse FVB
strain allele [1]. A recent study also reported that germline
SNPs of the SIPA1 gene are associated with major clinical
characteristics, such as estrogen receptor status and lymph
node metastasis in human breast cancer. The three SNPs
rs931127 (Lymph Node metastasis, p = 0.0139),
rs3741378 (ER status, p = 0.006; PR status, p = 0.035) and
rs746429 (Lymph Node metastasis, p = 0.0074) from the
SIPA1 gene were reported to be linked with different clin-
ical characteristics in a cohort from Southern California,
USA [4].
The SIPA1 protein has been related to increased breast
cancer metastasis in the mouse model. Polymorphisms of
the Sipa1 gene have significant effects on protein function
in the mouse model and SNPs in the human SIPA1 gene
are associated with major clinical markers. As a previous
study showed that SIPA1 RNAi down-regulation increased
the primary tumour burden in the mouse model, and
given the previous observations that the Sipa1 gene and
protein are associated with poor-prognosis markers and
metastasis, we considered the possibility that the SIPA1
gene may be correlated to breast carcinoma incidence as
well as prognosis. Therefore, this study investigated the
potential relationship between SIPA1 and the incidence of
human breast cancer by studying germline SNP frequency
(based on the common genotype representing common
disease phenotype hypothesis), utilizing a case-control
cohort from a European descendent population in
Queensland, Australia.
Results
A previous human epidemiology pilot study showed that
SNPs (rs931127, rs3741378 and rs746429) from the
SIPA1 gene are associated with important clinical markers
such as oestrogen receptor status and lymph node metas-
tasis. Molecular studies also showed that Sipa1 protein
levels in the cell are correlated to cell homeostasis and
metastasis strength in the mouse model and the polymor-
phism in the Sipa1 protein binding region influence the
protein binding efficiency. Increased primary breast
tumour size was also reported in the previous mouse
model study, which indicates that it is valuable to exam-
ine the possibility of a role for the SIPA1 gene in the initial
stage of breast carcinoma in humans.
The three selected SNPs were genotyped in both the Breast
Cancer group and the Control Group. The frequencies of
the genotypes of SNP rs931127 are listed in Table 1. Chi-
Square analysis of this data showed that no significant fre-
quency difference was observed between the Breast Can-
cer Group and the Control Group samples (χ2 = 0.73, df =
2, P = 0.695).
The genotype frequency of SNP rs746429 was analysed;
Chi-Square = 1, degrees of freedom = 2 with significance
= 0.601. No significant frequency difference between the
Breast Cancer group and the Control group was observed
for this SNP.
The frequencies of the genotypes of SNP rs3741378 are
also listed in Table 1. Significant frequency differences
were observed between the Breast Cancer Group and the
Control Group samples for this SNP. Chi-square analysis
showed that the CC genotype of rs3741378 is more fre-
quently observed in the Breast Cancer group compared to
the disease-free Control group. Furthermore, the data
shows that the TC genotype is more common in the con-
trols than the cancers, which indicates that having both
alleles may be protective in some manner. Due to the
extreme low counts for the TT allele, Hardy-Weinberg
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Table 1: Allele Frequencies for tested SNPs, including reported frequencies for CAUC 1 population.
Genotype Frequency
rs931127 Group Frequency AA AG GG Total
Breast Cancer N 58 89 36 183
% 31.69% 48.63% 19.67% 100%
Control N 52 97 34 183
% 28.42% 53.01% 18.58% 100%
CAUC 1 % 30% 60% 10% 100%
rs3741378 Group Frequency TT TC CC Total
Breast Cancer N 6 41 131 162
% 3.7% 25.31% 80.86% 100%
Control N 1 55 106 178
% 0.56% 30.89% 59.55% 100%
CAUC 1 % 3.2% 22.6% 74.2% 100%
rs746429 Group Frequency GG AG AA Total
Breast Cancer N 73 91 19 183
% 39.89% 49.73% 10.38% 100%
Control N 74 78 22 174
% 42.53% 44.83% 12.64% 100%
CAUC 1 % 37.9% 48.3% 13.8% 100%
Table 2: Analysis Results, rs3741378 Chi-square and HW-equilibrium for all SNPs.
Chi-Square Degrees of Freedom Significance
75.1 2 0.023
SNP HW- Probability: BC Group HW- Probability: Controls
rs3741378 0.224 0.029
rs931127 0.34 0.859
rs746429 0.837 0.226
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equilibrium analysis was performed to exclude the possi-
bility of experimental artefacts misleading the results. The
result of this and the Chi-square analysis for rs3741378
can be found in table 2. Other analyses were non-signifi-
cant at p = 0.607 and 0.695 for rs746429 and rs931127,
respectively.
Additionally, because of the extremely low count for the
TT genotype, the standard Chi-square method's assump-
tions are violated (requiring counts of at least 5 in all cat-
egories). Thus, a further analysis using CLUMP, a
computer method similar to Chi-square analysis that uses
a Monte-Carlo style probabilities rather than a set proba-
bility formula was performed. The results of CLUMP anal-
ysis confirm the original Chi-square results and are listed
in Table 3. It should be noted that one of the additional
analysis modes employed by CLUMP, which attempts to
lower error by collapsing low count groups into the next
lowest count did have significance above the 0.05 thresh-
old, though only by a very small amount.
Discussion
Signal-induced proliferation-associated 1 was first identi-
fied as a potential breast cancer metastasis modulator in
the mouse model. Molecular studies on this gene indicate
that it plays an important role in regulating cell adhesion
and modulating breast cancer metastasis. A preliminary
human epidemiology study also showed that germline
polymorphisms in the SIPA1 gene are correlated with sev-
eral major clinical characteristics, such as estrogen recep-
tor and lymph node metastasis status.
This study utilized a larger case-control population to
investigate the three SNPs published previously, in rela-
tion to breast cancer incidence. Of the three SNPs tested,
only rs3741378 showed a significant difference in fre-
quency between the breast cancer group and the disease
free control group. Since the CC genotype of this SNP was
observed to be more frequent in the Breast Cancer group
compared to the disease-free Control group and the TC
heterozygous genotype was more common in controls
than the cancer group, it indicates that the heterozygous
genotype may be protective against breast cancer (Odds
Ratio 0.5822, 95% CI 0.3614 to 0.938). This observation
also indicates that SNP rs3741378 may play a role as a
potential sporadic breast cancer predisposition gene/SNP.
In the previous pilot study this SNP showed a significant
correlation to both oestrogen receptor and progesterone
receptor status. It is possible that this exonic missense SNP
which has a Ser (S) to Phe (F) change, altering a
hydrophilic residue (S) to a hydrophobic residue (F) sig-
nificantly changes the protein functions of SIPA1. This
may thus have a functional role in the hormonal status
biology of breast carcinogenesis. The observed accumula-
tion of CT genotypes in controls may be a reflection of
increased substrate interactivity of the SIPA1 proteins
derived from CT genotype cells, through interactions with
different mitogenic pathways or alterations to the gene's
cell adhesion functions. This SNP has been previously
associated with oestrogen and progesterone receptor sta-
tus, and it is possible that some of the protective functions
of a CT genotype may be mediated through effects on
these pathways.
It is important to note, however, that the low counts for
the rare TT genotype in this population may be violating
statistical assumptions and indicating a false relationship
between this polymorphism and breast cancer risk. The
non-parametric CLUMP analysis agreed with the initial
Chi-square analysis, adding weight to the possibility of
the observed relationship. The significant Hardy-Wein-
berg result for the control population throws some sup-
port to the possibility of a false relationship, perhaps
driven by selection bias. This, however, may be an effect
of the extreme rarity of the TT genotype, as both popula-
tions are within Hardy-Weinberg equilibrium for all other
SNPs, indicating little or no selection bias for these SNPs.
The T4 statistic collapses the lowest expected counts into
the next category, somewhat abrogating the effect of the
rarity of the TT genotype and its extreme closeness to sig-
nificance does argue for some veracity to the observed
relationship. The failure of the T4 statistic of CLUMP to
reach the χ2 significance of 0.05, even by the tiny margin
observed, is an indicator that additional studies in larger,
but still tightly localised populations should be carried
out to more accurately determine the strength and nature
of the effect that this SIPA1 SNP has on breast cancer risk.
In addition, there was insufficiently detailed ER and PgR
status, or other epidemiological information for the pop-
ulation to allow meaningful analysis in this present study.
Table 3: CLUMP analysis of rs3741378.
Rs3741378 T1 analysis (mimics standard Chi-Square) T4 analysis 
(collapses low-count categories into the next lowest category)
Chi-Squared stat 7.5139 4.9882
Degrees of freedom 2 1
Probability 0.0234 0.0503
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Future larger studies that have this information available
are warranted.
Furthermore, the other two SNPs of SIPA1 screened;
rs931127 which is a 5' near gene SNP and rs746429 which
is a synonymous (Ala (A) to Ala (A)) SNP, did not show
significant association with breast cancer, yet were
reported to be associated with lymph node metastasis in
the previous study. This suggests that SIPA1 may have dif-
ferent or shifted function in different stages of breast car-
cinogenesis, with different domains; having the increased
tumourgenesis susceptibility function with the domain
where SNP rs3741378 resides and promotes metastasis
via the domain SNP rs746429 resides.
A recent case-control study from Gaudet et al. reported a
similar trend, though the difference in their population
did not reach statistical significance. The Gaudet et al.
group explored the same SNPs as this research in a Polish
(1995 cases, 2296 control) and a British cohort (2142
cases, 2257 controls). They reported a suggestion of an
increased risk of breast cancer associated with the TT gen-
otype of the SNP rs3741378 [5]. Both the Gaudet group
and this research identified a potential relationship
between this SNP and breast cancer risk. The inconsist-
ency of the significance of the association between this
study and the Gaudet is likely best explained by the
diverse nature of the populations studied, through either
environmental or genetic variance. The ratio of the TT gen-
otype in the control samples has a wider range of diversity
between the Gaudet study and this investigation, with the
TT genotype comprising 0.62% of the control group for
this study compared to 1.8% in the pooled study from the
Gaudet group, both of which are less than the CAUC 1
population, indicating that this SNP may be highly varia-
ble in different areas. The difference in this rare allele fre-
quency may explain the slight inconsistency in strength of
association identified between the researches. However,
the two independent groups did identifying a similar rela-
tionship, only differing in the strength and significance of
the relationship identified. This, as well as previous func-
tional work, adds support to the involvement of the SIPA1
gene and its SNPs in breast cancer susceptibility.
Conclusion
The novel breast carcinogenesis gene SIPA1 has important
molecular functions as a breast cancer metastasis modula-
tor. A preliminary human pilot epidemiology study indi-
cated that germline single nucleotide polymorphisms of
SIPA1 are significantly correlated to major clinical factors,
such as estrogen receptor status and increased lymph node
metastasis. This study provides observations that one of
these SNPs may also act as a breast cancer predisposition
marker. Further molecular functional analysis of SIPA1
and its SNPs in the human population is needed to prop-
erly elaborate the function of this gene and its potential as
breast carcinogenesis marker. This study highlights the
importance of SNPs of the SIPA1 gene in breast carcinoma
and that the screened SNPs are not only markers of poor
prognosis as previously described, but may also act as pre-
disposition markers. The protein expression level of SIPA1
in the mouse model has been linked to breast cancer
metastasis propensity as increased levels lead to increased
metastasis and decreased levels lead to a decreased
amount of lung metastasis. This indicates that SIPA1 tran-
scription at the genetic, expression and protein level may
play an integral role in breast carcinoma and represent a
key factor in the evolution of this disease. Additionally,
this research further supported the hypothesis that inher-
ited subtle genetic variations may be associated with not
only with cancer metastasis but also with cancer predispo-
sition.
Methods
Study Cohort
The population screened was comprised of 200 female
individuals diagnosed with breast cancer and a control
population of 200 females with no cancer history at all.
The affected and control populations were matched for
age and all were of Caucasian ethnicity, as has been previ-
ously described [6]. No other risk factors were controlled
for. Samples were recruited through collaboration with
the Pathology Department of the Gold Coast Hospital,
Queensland Australia and additional affected samples, as
well as the entire control population, were obtained
through the Genomics Research Centre of Griffith Univer-
sity [6]. All participants gave informed consent. The study
was conducted under the approval of the Gold Coast Hos-
pital and Griffith University Ethics Committees. The refer-
ence numbers for these approvals are 9702 and MSC/07/
08/HREC, respectively.
Genotyping
The SNPs genotyped in this study were identified in a pre-
vious study [4], and were chosen based on the genomic
location of known SNPs (from the NCBI SNP database)
that are within the regulatory or coding regions of SIPA1
[4]. The NCBI SNP designation rs931127 polymorphism
(-313G>A) is 313 base pairs upstream of the 5'-untrans-
lated region of SIPA1 and considered as within the pro-
moter region of the gene. The other two SNPs are located
within coding regions, rs3741378 is a missense SNP
within exon 1 (545C>T [F182S]) and rs746429 is a synon-
ymous SNP within exon 12 (2760G>A [A920A]). Quality
control for genotyping was provided by including 3 sam-
ples of CEPH family DNA (mention commercial source of
DNA), repeated 4 times in each PCR plate. Genotyping
results for these four samples were identical for all PCRs
and concordance rates were 100%.
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SNP analysis was carried out using TaqMan Universal PCR
Master Mix (Applied Biosystems, USA) and TaqMan SNP
Genotyping Assays (Applied Biosystems, USA).
The TaqMan SNP Genotyping Assays are composed of
primer and probes that are pre-designed and validated by
the company. The probes are conjugated with VIC-MGB
or FAM-MGB dyes, one to each allele. Once the PCR is
complete the 7900HT Sequencing Detection System
(Applied Biosystem, USA) distributes the data points
according to the signals generated depending on the allele
composition of each patient. The genotype determination
was made by a signal distribution comparison to several
control samples (derived from CEPH Family DNA) for
which the genotypes are known. Assays were carried out
following the instructions from the company. The
amount of volume required for each 5 μl reaction was as
follows, (10 ng of DNA needs to be dried before adding
the other reagents), TaqMan Universal PCR Master Mix;
2.5 μl, TaqMan SNP Genotyping Assay; 0.25 μl and 2.25
μl of DEPC Treated Water (Quality Biological, INC, USA).
The reaction conditions were as follows; 95°C for 10 min-
utes, and 50 cycles of 92°C for 15 seconds and 60°C for 1
minute. After the PCR was finished, the plates were then
read by the 7900HT Sequencing Detection System,
according to manufacturer protocols (Applied Biosys-
tems, USA).
Statistical Analyses
To determine whether any significant differences in poly-
morphism frequencies occurred between the case and
control populations, allele and genotype frequencies were
compared using the chi-square method and the Monte
Carlo style CLUMP analysis program [6,7]. The study was
estimated to have an approximately 75% power to detect
positive association of a SNP with low effect.
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